2024-09-02 - Analysis Report
## REGN Stock Analysis Report

This report provides an analysis of Regeneron Pharmaceuticals, Inc. (REGN) based on the provided data.

**Company Overview:** 
Regeneron Pharmaceuticals, Inc. is a leading biotechnology company focused on discovering, developing, and commercializing life-transforming medicines for serious diseases.

**1. Performance vs. S&P 500 (VOO):**

* **REGN Cumulative Return:** 159.56%
* **VOO Cumulative Return:** 89.66%
* **Divergence:** 69.9% (Relative Divergence: 95.82%)

This shows that REGN has significantly outperformed the S&P 500 (VOO) over the period analyzed. It has consistently been in the top 95.82% range of historical performance relative to VOO.

**2. Recent Price Movements:**

* **Closing Price:** 1184.69
* **5-day Moving Average:** 1192.81
* **20-day Moving Average:** 1158.3
* **60-day Moving Average:** 1090.18

The stock is currently trading slightly below its 5-day moving average, indicating potential short-term weakness. However, it remains above both the 20-day and 60-day moving averages, suggesting a bullish trend in the medium to long term.

**3. Technical Indicators:**

* **RSI:** 73.51
* **PPO:** -0.17
* **Delta_Previous_Relative_Divergence:** -4.18 (Short-term bearish)
* **Expected_Return:** 3.13% (Maximum 5-year expected return on investment)

The RSI indicates that the stock is currently in overbought territory, suggesting a potential pullback. The negative PPO value indicates a bearish momentum. However, the positive Expected Return suggests potential long-term growth.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue | 
|---|---|---|
| 2024-08-01 | 13.25 | 3.55 B$ |
| 2024-05-02 | 6.7 | 3.15 B$ |
| 2023-11-02 | 9.48 | 3.36 B$ |
| 2023-08-03 | 9.05 | 3.16 B$ |
| 2024-08-01 | 9.05 | 3.16 B$ |

The latest earnings report (2024-08-01) showed a significant increase in both EPS and revenue compared to previous quarters. This indicates positive financial performance and strong growth prospects.

**5. Overall Analysis:**

REGN has historically outperformed the S&P 500 and has shown consistent growth. Despite recent short-term bearish signals, the stock remains in a bullish trend in the medium to long term. Positive earnings and strong financial performance indicate a bright future.

**6. Key Takeaways:**

* **Strengths:**
    * Strong historical performance
    * Positive earnings and revenue growth
    * Strong long-term expected return
* **Weaknesses:**
    * Overbought territory based on RSI
    * Short-term bearish signals

**Conclusion:**

While some short-term bearish signals exist, REGN remains a strong investment candidate with a solid track record and promising growth prospects. It is important to monitor the stock closely and consider the overall market conditions before making investment decisions. 
